Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BDTX-189 |
Synonyms | |
Therapy Description |
BDTX-189 is an inhibitor of ERBB2 (HER2) and EGFR mutations, which potentially inhibits tumor growth (J Clin Oncol 38: 2020 (suppl; abstr TPS3665). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BDTX-189 | BDTX189|BDTX 189|Tuxobertinib | EGFR Inhibitor (Pan) 62 HER2 Inhibitor 42 | BDTX-189 is an inhibitor of ERBB2 (HER2) and EGFR mutations, which potentially inhibits tumor growth (J Clin Oncol 38: 2020 (suppl; abstr TPS3665). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04209465 | Phase I | BDTX-189 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | Terminated | USA | FRA | ESP | 1 |